Supernus Pharmaceuticals Inc (SUPN)

Debt-to-capital ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	—	—	—	—	—	0	0	400,382	379,252	374,788	370,383	366,038	361,751	357,521	353,349	349,232	345,170	341,163	337,210	333,310
Total stockholders’ equity	US$ in thousands	1	912,191	919,908	912,150	0	852,798	841,434	828,446	815,851	810,468	785,579	754,444	744,858	708,879	665,974	613,383	595,428	557,257	522,904	480,018
Debt-to-capital ratio		0.00	0.00	0.00	0.00	—	0.00	0.00	0.33	0.32	0.32	0.32	0.33	0.33	0.34	0.35	0.36	0.37	0.38	0.39	0.41

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $1K)
= 0.00

Supernus Pharmaceuticals Inc's debt-to-capital ratio has remained consistently low from Q2 2022 to Q3 2023, ranging from 0.31 to 0.33. However, in Q1 2023, there was a notable increase in the ratio to 0.35, indicating a temporary increase in the company's debt relative to its capital during that period. Overall, the low and stable debt-to-capital ratio suggests that Supernus Pharmaceuticals Inc has been effectively managing its debt levels in relation to its capital structure.